Bausch + Lomb (BLCO) Set to Post Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is anticipated to release its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of $0.2145 per share and revenue of $1.37 billion for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, July 29th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.01). The firm had revenue of $1.39 billion during the quarter, compared to analysts’ expectations of $1.37 billion. Bausch + Lomb had a positive return on equity of 4.14% and a negative net margin of 3.21%. Bausch + Lomb’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.18) earnings per share. On average, analysts expect Bausch + Lomb to post $0.81 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.

Bausch + Lomb Stock Performance

Shares of BLCO stock opened at $16.91 on Wednesday. The business’s fifty day simple moving average is $17.15 and its 200-day simple moving average is $16.47. The company has a market cap of $6.04 billion, a PE ratio of -35.23, a PEG ratio of 0.52 and a beta of 0.56. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.79. Bausch + Lomb has a 12-month low of $14.44 and a 12-month high of $18.92.

Insider Transactions at Bausch + Lomb

In other news, Director Eschenbach Andrew C. Von sold 12,500 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $16.50, for a total value of $206,250.00. Following the completion of the transaction, the director directly owned 69,792 shares in the company, valued at $1,151,568. This trade represents a 15.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Frederick Munsch sold 52,900 shares of Bausch + Lomb stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $16.78, for a total value of $887,662.00. Following the sale, the chief accounting officer directly owned 45,831 shares of the company’s stock, valued at $769,044.18. This trade represents a 53.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 71,459 shares of company stock worth $1,194,370 over the last three months. Corporate insiders own 1.45% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on BLCO. Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a research report on Tuesday, September 15th. Evercore set a $17.00 target price on Bausch + Lomb in a research note on Monday, July 6th. Leerink Partners assumed coverage on Bausch + Lomb in a research report on Wednesday, September 9th. They set an “outperform” rating and a $24.00 target price on the stock. Weiss Ratings upgraded Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. Finally, Citigroup increased their price target on Bausch + Lomb from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $19.46.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.